Hims & Hers Health Inc. (HIMS) saw its stock soar 6.94% on Monday, following the company's announcement of key leadership appointments aimed at strengthening its focus on quality, safety, and regulatory compliance.
The telehealth firm appointed Deb Autor, a former deputy commissioner at the U.S. Food and Drug Administration (FDA), to its board of directors. Autor brings over 30 years of experience in pharmaceutical quality, compliance, regulatory programs, and consumer protection. During her tenure at the FDA, she oversaw inspections, criminal investigations, and international operations for the agency.
Additionally, Hims & Hers named Janet Stevens as its Global Head of Quality & Safety. Stevens has spent her entire career in pharmaceutical quality assurance, operations, and engineering. She previously served as the Chief Quality Officer at Hillrom, where she helped the company achieve top-quartile results in global quality regulations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。